TWEAK/Fn14 axis: The current paradigm of tissue injury-inducible function in the midst of complexities

Seminars in Immunology

Volumn 26, Issue 3, 2014, Pages 229-236

  Burkly, Linda C ^a  

^a BIOGEN   (United States)

Author keywords

Cancer; Fibrosis; Fn14; Inflammation; Tissue injury; TWEAK

Indexed keywords

FGF INDUCIBLE MOLECULE 14; LIGAND; RECEPTOR; TNF LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG; TNFSF12 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TWEAK RECEPTOR;

AUTOIMMUNE DISEASE; CANCER MODEL; CELL DEATH; CHRONIC DISEASE; CHRONIC INFLAMMATION; FIBROSIS; HUMAN; INFLAMMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STEM CELL; STROMA CELL; TISSUE INJURY; TISSUE REACTION; TISSUE REGENERATION; TISSUE REPAIR; UPREGULATION; ANIMAL; IMMUNOLOGY; METABOLISM; NEOPLASM; SIGNAL TRANSDUCTION;

ANIMALS; FIBROSIS; HUMANS; INFLAMMATION; NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTORS;

EID: 84904044989     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2014.02.006     Document Type: Review

References (59)

1. Dvorak H.F. Tumors: wounds that do not heal: similarities between tumor stroma generation and wound healing. N Engl J Med 1986, 315:1650-1659.
2. Wynn T.A., Ramalingam T.R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012, 18:1028-1040.
3. Chicheportiche Y., Bourdon P.R., Xu H., Hsu Y.M., Scott H., Hession C., et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997, 272:32401-32410.
4. Meighan-Mantha R.L., Hsu D.K., Guo Y., Brown S.A., Feng S.L., Peifley K.A., et al. The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem 1999, 274:33166-33176.
5. Wiley S.R., Cassiano L., Lofton T., Davis-Smith T., Winkles J.A., Lindner V., et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001, 15:837-846.
6. Burkly L.C., Michaelson J.S., Hahm K., Jakubowski A., Zheng T.S. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007, 40:1-16.
7. Winkles J.A. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008, 7:411-425.
8. Burkly L.C., Michaelson J.S., Zheng T.S. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev 2011, 244:99-114.
9. Maecker H., Varfolomeev E., Kischkel F., Lawrence D., LeBlanc H., Lee W., et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell 2005, 123:931-944.
10. Nakayama M., Kayagaki N., Yamaguchi N., Okumura K., Yagita H. Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med 2000, 192:1373-1380.
11. Desplat-Jego S., Feuillet L., Creidy R., Malikova I., Rance R., Khrestchatisky M., et al. TWEAK is expressed at the cell surface of monocytes during multiple sclerosis. J Leukoc Biol 2009, 85:132-135.
12. Kaplan M.J., Lewis E.E., Shelden E.A., Somers E., Pavlic R., McCune W.J., et al. The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol 2002, 169:6020-6029.
13. Dohi T., Burkly L.C. The TWEAK/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases: focus on inflammatory bowel diseases. J Leukoc Biol 2012, 92:265-279.
14. Roos C., Wicovsky A., Muller N., Salzmann S., Rosenthal T., Kalthoff H., et al. Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. J Immunol 2010, 185:1593-1605.
15. Burkly L.C., Dohi T. The TWEAK/Fn14 pathway in tissue remodeling: for better or for worse. Adv Exp Med Biol 2011, 691:305-322.
16. Kruglov A.A., Lampropoulou V., Fillatreau S., Nedospasov S.A. Pathogenic and protective functions of TNF in neuroinflammation are defined by its expression in T lymphocytes and myeloid cells. J Immunol 2011, 187:5660-5670.
17. 3+ Treg-cell function and disease suppression in EAE. Eur J Immunol 2012, 42:403-412.
18. Zheng T.S., Burkly L.C. No end in site: TWEAK/Fn14 activation and autoimmunity associated end-organ pathologies. J Leukoc Biol 2008, 84:338-347.
19. Wajant H. The TWEAK-Fn14 system as a potential drug target. Br J Pharmacol 2013, 170:748-764.
20. Salzmann S., Seher A., Trebing J., Weisenberger D., Rosenthal A., Siegmund D., et al. Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity. J Biol Chem 2013, 288:13455-13466.
21. Enwere E.K., Holbrook J., Lejmi-Mrad R., Vineham J., Timusk K., Sivaraj B., et al. TWEAK and cIAP1 regulate myoblast fusion through the noncanonical NF-kappaB signaling pathway. Sci Signal 2012, 5:ra75.
22. Dogra C., Changotra H., Mohan S., Kumar A. Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-kappaB and degradation of MyoD protein. J Biol Chem 2006, 281:10327-10336.
23. Girgenrath M., Weng S., Kostek C.A., Browning B., Wang M., Brown S.A., et al. TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J 2006, 25:5826-5839.
24. Dogra C., Changotra H., Wedhas N., Qin X., Wergedal J.E., Kumar A. TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J 2007, 21:1857-1869.
25. Tran N.L., McDonough W.S., Savitch B.A., Fortin S.P., Winkles J.A., Symons M., et al. Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome. Cancer Res 2006, 66:9535-9542.
26. Watts G.S., Tran N.L., Berens M.E., Bhattacharyya A.K., Nelson M.A., Montgomery E.A., et al. Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma. Int J Cancer 2007, 121:2132-2139.
27. Willis A.L., Tran N.L., Chatigny J.M., Charlton N., Vu H., Brown S.A., et al. The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol Cancer Res 2008, 6:725-734.
28. Tirnitz-Parker J.E., Viebahn C.S., Jakubowski A., Klopcic B.R., Olynyk J.K., Yeoh G.C., et al. Tumor necrosis factor-like weak inducer of apoptosis is a mitogen for liver progenitor cells. Hepatology 2010, 52:291-302.
29. Wu F., Guo L., Jakubowski A., Su L., Li W.C., Bonner-Weir S., et al. TNF-like weak inducer of apoptosis (TWEAK) promotes beta cell neogenesis from pancreatic ductal epithelium in adult mice. PLoS ONE 2013, 8:e72132.
30. Hotta K., Sho M., Yamato I., Shimada K., Harada H., Akahori T., et al. Direct targeting of fibroblast growth factor-inducible 14 protein protects against renal ischemia reperfusion injury. Kidney Int 2011, 79:179-188.
31. Kuramitsu K., Sverdlov D.Y., Liu S.B., Csizmadia E., Burkly L., Schuppan D., et al. Failure of fibrotic liver regeneration in mice is linked to a severe fibrogenic response driven by hepatic progenitor cell activation. Am J Pathol 2013, 183:182-194.
32. Mittal A., Bhatnagar S., Kumar A., Lach-Trifilieff E., Wauters S., Li H., et al. The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J Cell Biol 2010, 188:833-849.
33. Mittal A., Bhatnagar S., Kumar A., Paul P.K., Kuang S., Kumar A. Genetic ablation of TWEAK augments regeneration and post-injury growth of skeletal muscle in mice. Am J Pathol 2010, 177:1732-1742.
34. Novoyatleva T., Diehl F., van Amerongen M.J., Patra C., Ferrazzi F., Bellazzi R., et al. TWEAK is a positive regulator of cardiomyocyte proliferation. Cardiovasc Res 2010, 85:681-690.
35. Son A., Oshio T., Kawamura Y.I., Hagiwara T., Yamazaki M., Inagaki-Ohara K., et al. TWEAK/Fn14 pathway promotes a T helper 2-type chronic colitis with fibrosis in mice. Mucosal Immunol 2013, 6:1131-1142.
36. Ucero A.C., Benito-Martin A., Fuentes-Calvo I., Santamaria B., Blanco J., Lopez-Novoa J.M., et al. TNF-related weak inducer of apoptosis (TWEAK) promotes kidney fibrosis and Ras-dependent proliferation of cultured renal fibroblast. Biochim Biophys Acta 2013, 1832:1744-1755.
37. Xia Y., Campbell S.R., Broder A., Herlitz L., Abadi M., Wu P., et al. Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis. Clin Immunol 2012, 145:108-121.
38. Chapman M.S., Wu L., Amatucci A., Ho S.N., Michaelson J.S. TWEAK signals through JAK-STAT to induce tumor cell apoptosis. Cytokine 2013, 61:210-217.
39. Kawashima R., Kawamura Y.I., Oshio T., Son A., Yamazaki M., Hagiwara T., et al. Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice-a pathway associated with ulcerative colitis. Gastroenterology 2011, 141. 2119-2129.e2118.
40. Datta A., Alexander R., Sulikowski M.G., Nicholson A.G., Maher T.M., Scotton C.J., et al. Evidence for a functional thymic stromal lymphopoietin signaling axis in fibrotic lung disease. J Immunol 2013, 191:4867-4879.
41. Oh M.H., Oh S.Y., Yu J., Myers A.C., Leonard W.J., Liu Y.J., et al. IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin. J Immunol 2011, 186:7232-7242.
42. Friedman S.L., Sheppard D., Duffield J.S., Violette S. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med 2013, 5(167):167sr1.
43. Novoyatleva T., Schymura Y., Janssen W., Strobl F., Swiercz J.M., Patra C., et al. Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction. Basic Res Cardiol 2013, 108:325.
44. Culp P.A., Choi D., Zhang Y., Yin J., Seto P., Ybarra S.E., et al. Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms. Clin Cancer Res 2010, 16:497-508.
45. Yin X., Luistro L., Zhong H., Smith M., Nevins T., Schostack K., et al. RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response. Clin Cancer Res 2013, 19:5686-5698.
46. Kawakita T., Shiraki K., Yamanaka Y., Yamaguchi Y., Saitou Y., Enokimura N., et al. Functional expression of TWEAK in human hepatocellular carcinoma: possible implication in cell proliferation and tumor angiogenesis. Biochem Biophys Res Commun 2004, 318:726-733.
47. Kwon O.H., Park S.J., Kang T.W., Kim M., Kim J.H., Noh S.M., et al. Elevated fibroblast growth factor-inducible 14 expression promotes gastric cancer growth via nuclear factor-kappaB and is associated with poor patient outcome. Cancer Lett 2012, 314:73-81.
48. Pelekanou V., Notas G., Theodoropoulou K., Kampa M., Takos D., Alexaki V.I., et al. Detection of the TNFSF members BAFF, APRIL, TWEAK and their receptors in normal kidney and renal cell carcinomas. Anal Cell Pathol 2011, 34:49-60.
49. Pettersen I., Baryawno N., Abel F., Bakkelund W.H., Zykova S.N., Winberg J.O., et al. Expression of TWEAK/Fn14 in neuroblastoma: implications in tumorigenesis. Int J Oncol 2013, 42:1239-1248.
50. Wang S., Zhan M., Yin J., Abraham J.M., Mori Y., Sato F., et al. Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene 2006, 25:3346-3356.
51. Fortin S.P., Ennis M.J., Savitch B.A., Carpentieri D., McDonough W.S., Winkles J.A., et al. Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function. Mol Cancer Res 2009, 7:1871-1881.
52. Tran N.L., McDonough W.S., Donohue P.J., Winkles J.A., Berens T.J., Ross K.R., et al. The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol 2003, 162:1313-1321.
53. Tran N.L., McDonough W.S., Savitch B.A., Sawyer T.F., Winkles J.A., Berens M.E. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NF-kappaB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 2005, 280:3483-3492.
54. Michaelson J.S., Cho S., Browning B., Zheng T.S., Lincecum J.M., Wang M.Z., et al. Tweak induces mammary epithelial branching morphogenesis. Oncogene 2005, 24:2613-2624.
55. de Visser K.E., Eichten A., Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6:24-37.
56. Dohi T., Borodovsky A., Wu P., Shearstone J.R., Kawashima R., Runkel L., et al. TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis. Gastroenterology 2009, 136:912-923.
57. Kaduka Y., Takeda K., Nakayama M., Kinoshita K., Yagita H., Okumura K. TWEAK mediates anti-tumor effect of tumor-infiltrating macrophage. Biochem Biophys Res Commun 2005, 331:384-390.
58. Michaelson J.S., Amatucci A., Kelly R., Su L., Garber E., Day E.S., et al. Development of an Fn14 agonistic antibody as an anti-tumor agent. mAbs 2011, 3:362-375.
59. Trebing J., Lang I., Chopra M., Salzmann S., Moshir M., Silence K., et al. A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo. mAbs 2013, 6.